Top-Rated StocksTop-RatedMost-Upgraded StocksMost-Upgraded Immunovant Stock Price, News & Analysis (NASDAQ:IMVT) $40.05 +0.92 (+2.35%) (As of 02:10 PM ET) Add Compare Share Share Today's Range$38.14▼$40.2150-Day Range$20.28▼$39.9652-Week Range$13.67▼$44.19Volume1.45 million shsAverage Volume1.38 million shsMarket Capitalization$5.79 billionP/E RatioN/ADividend YieldN/APrice Target$42.54 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Immunovant MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside6.6% Upside$42.54 Price TargetShort InterestBearish11.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 14 Articles This WeekInsider TradingAcquiring Shares$58 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.82) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.46 out of 5 starsMedical Sector889th out of 948 stocksBiological Products, Except Diagnostic Industry159th out of 164 stocks 2.5 Analyst's Opinion Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.54, Immunovant has a forecasted upside of 6.6% from its current price of $39.89.Amount of Analyst CoverageImmunovant has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.64% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immunovant has recently increased by 5.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMVT. Previous Next 1.1 News and Social Media Coverage News SentimentImmunovant has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Immunovant this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have bought 4,182.41% more of their company's stock than they have sold. Specifically, they have bought $58,000,008.00 in company stock and sold $1,354,378.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Immunovant is held by insiders.Percentage Held by Institutions42.45% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($1.82) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -20.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -20.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 22.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immunovant Stock (NASDAQ:IMVT)Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.Read More IMVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMVT Stock News HeadlinesDecember 1, 2023 | finance.yahoo.comHere’s Why Immunovant (IMVT) Outperformed in Q3November 29, 2023 | markets.businessinsider.comImmunovant’s IMVT-1402 Shows Promising Phase 1 Results and Market Opportunity Following Competitor’s Trial FailureDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 28, 2023 | markets.businessinsider.comImmunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNovember 28, 2023 | markets.businessinsider.comImmunovant Announces Positive Initial Data From Phase 1 Study Of IMVT-1402November 26, 2023 | americanbankingnews.comJulia G. Butchko Sells 3,265 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockNovember 26, 2023 | americanbankingnews.comEva Renee Barnett Sells 4,055 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockNovember 26, 2023 | americanbankingnews.comPeter Salzmann Sells 16,217 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 26, 2023 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) CEO Sells $531,593.26 in StockNovember 25, 2023 | finance.yahoo.comImmunovant Inc CEO Peter Salzmann Sells Over 16,000 SharesNovember 18, 2023 | markets.businessinsider.comPromising Prospects of Immunovant’s Clinical Trials Driving Growth PotentialNovember 15, 2023 | markets.businessinsider.comWhere Immunovant Stands With AnalystsNovember 14, 2023 | finance.yahoo.comImmunovant, Inc.'s (NASDAQ:IMVT) Intrinsic Value Is Potentially 60% Above Its Share PriceNovember 14, 2023 | seekingalpha.comImmunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune ArenaNovember 13, 2023 | finance.yahoo.comImmunovant to Present at Upcoming Investor ConferencesNovember 10, 2023 | finance.yahoo.comImmunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in FocusNovember 9, 2023 | finance.yahoo.comImmunovant Inc (IMVT) Reports Fiscal Q2 Results: R&D Investments Surge Amidst Clinical ProgressNovember 9, 2023 | benzinga.comRecap: Immunovant Q2 EarningsNovember 9, 2023 | finance.yahoo.comImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023November 1, 2023 | msn.comImmunovant (IMVT) Price Target Increased by 19.11% to 48.41October 28, 2023 | finance.yahoo.comInsider Sell: Chief Legal Officer Mark Levine Sells 4,107 Shares of Immunovant IncOctober 26, 2023 | finanznachrichten.deHanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business UpdateOctober 25, 2023 | msn.comPiper Sandler Maintains Immunovant (IMVT) Overweight RecommendationOctober 18, 2023 | msn.comCantor Fitzgerald Maintains Immunovant (IMVT) Overweight RecommendationOctober 14, 2023 | msn.comUBS Upgrades Immunovant (IMVT)October 12, 2023 | finance.yahoo.comCFO Eva Barnett Sells 4,557 Shares of Immunovant Inc (IMVT)See More Headlines Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/01/2023Next Earnings (Estimated)2/02/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$42.54 High Stock Price Target$57.00 Low Stock Price Target$21.00 Potential Upside/Downside+10.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-210,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.07% Return on Assets-64.50% Debt Debt-to-Equity RatioN/A Current Ratio7.23 Quick Ratio7.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.74 per share Price / Book22.10Miscellaneous Outstanding Shares144,660,000Free Float137,718,000Market Cap$5.56 billion OptionableNot Optionable Beta0.66 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Frank M. Torti M.B.A. (Age 44)M.D., Executive Chairperson of the Board Comp: $92.5kDr. Peter Salzmann M.B.A. (Age 55)M.D., CEO & Director Comp: $1.02MMs. Eva Renee Barnett M.B.A. (Age 43)Chief Financial Officer Comp: $871.07kDr. William L. Macias M.D. (Age 65)Ph.D., Chief Medical Officer Comp: $719.88kDr. Jay S. Stout Ph.D. (Age 60)Chief Technology Officer Dr. Chau Cheng M.B.A.Ph.D., Vice President of Investor RelationsMr. Mark S. Levine (Age 50)Chief Legal Officer & Corporate Secretary Ms. Lauren Schrier M.B.A.Vice President of MarketingMs. Christine BlodgettVice President of Human ResourcesDr. Julia G. Butchko Ph.D. (Age 52)Chief Development Officer Comp: $531kMore ExecutivesKey CompetitorsHalozyme TherapeuticsNASDAQ:HALOAbcamNASDAQ:ABCMCRISPR TherapeuticsNASDAQ:CRSPVaxcyteNASDAQ:PCVXExelixisNASDAQ:EXELView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 168,608 shares on 12/1/2023Ownership: 0.117%Deutsche Bank AGSold 107,689 shares on 11/24/2023Ownership: 0.024%Peter SalzmannSold 16,217 sharesTotal: $531,593.26 ($32.78/share)Julia G ButchkoSold 3,265 sharesTotal: $107,026.70 ($32.78/share)Eva Renee BarnettSold 4,055 sharesTotal: $132,922.90 ($32.78/share)View All Insider TransactionsView All Institutional Transactions IMVT Stock Analysis - Frequently Asked Questions Should I buy or sell Immunovant stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares. View IMVT analyst ratings or view top-rated stocks. What is Immunovant's stock price target for 2024? 13 Wall Street research analysts have issued twelve-month price objectives for Immunovant's stock. Their IMVT share price targets range from $21.00 to $57.00. On average, they expect the company's stock price to reach $42.54 in the next twelve months. This suggests a possible upside of 6.6% from the stock's current price. View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts. How have IMVT shares performed in 2023? Immunovant's stock was trading at $17.75 at the beginning of 2023. Since then, IMVT stock has increased by 124.7% and is now trading at $39.89. View the best growth stocks for 2023 here. Are investors shorting Immunovant? Immunovant saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 7,060,000 shares, an increase of 5.5% from the October 31st total of 6,690,000 shares. Based on an average daily volume of 2,150,000 shares, the short-interest ratio is presently 3.3 days. Approximately 11.6% of the shares of the company are sold short. View Immunovant's Short Interest. When is Immunovant's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 2nd 2024. View our IMVT earnings forecast. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.45) EPS for the quarter, meeting the consensus estimate of ($0.45). What ETFs hold Immunovant's stock? ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ Chaikin U.S. Small Cap ETF (CSML). What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ). Who are Immunovant's major shareholders? Immunovant's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (5.36%), Alpine Global Management LLC (0.87%), Fred Alger Management LLC (0.82%), Avidity Partners Management LP (0.81%), Redmile Group LLC (0.76%) and Armistice Capital LLC (0.72%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IMVT) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.